<SEC-DOCUMENT>0001919246-26-000063.txt : 20260420
<SEC-HEADER>0001919246-26-000063.hdr.sgml : 20260420
<ACCEPTANCE-DATETIME>20260420170041
ACCESSION NUMBER:		0001919246-26-000063
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260410
FILED AS OF DATE:		20260420
DATE AS OF CHANGE:		20260420

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GAY JOHN M.
		CENTRAL INDEX KEY:			0001765684
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41964
		FILM NUMBER:		26875823

	MAIL ADDRESS:	
		STREET 1:		C/O NOVAN, INC.
		STREET 2:		4105 HOPSON ROAD
		CITY:			MORRISVILLE
		STATE:			NC
		ZIP:			27560

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pelthos Therapeutics Inc.
		CENTRAL INDEX KEY:			0001919246
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				863335449
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		4020 STIRRUP CREEK DRIVE
		STREET 2:		SUITE 110
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-908-2422

	MAIL ADDRESS:	
		STREET 1:		4020 STIRRUP CREEK DRIVE
		STREET 2:		SUITE 110
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Channel Therapeutics Corp
		DATE OF NAME CHANGE:	20241118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Chromocell Therapeutics Corp
		DATE OF NAME CHANGE:	20220323
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>wk-form3_1776718839.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0607</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2026-04-10</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001919246</issuerCik>
        <issuerName>Pelthos Therapeutics Inc.</issuerName>
        <issuerTradingSymbol>PTHS</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001765684</rptOwnerCik>
            <rptOwnerName>GAY JOHN M.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>C/O PELTHOS THERAPEUTICS INC.</rptOwnerStreet1>
            <rptOwnerStreet2>4020 STIRRUP CREEK DRIVE, SUITE 110</rptOwnerStreet2>
            <rptOwnerCity>DURHAM</rptOwnerCity>
            <rptOwnerState>NC</rptOwnerState>
            <rptOwnerZipCode>27703</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>30518</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>13.50</value>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2026-07-02</value>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-07-02</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>93000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Represents 30,518 shares of common stock, par value $0.0001 per share (&quot;Common Stock&quot;) of Pelthos Therapeutics Inc. (the &quot;Issuer&quot;), issuable upon settlement of restricted stock units of the Issuer (&quot;RSUs&quot;) granted to the reporting person on July 2, 2025 pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the &quot;2023 Plan&quot;), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third (1/3) of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such vesting date.</footnote>
        <footnote id="F2">On July 2, 2025, the reporting person was granted stock options to purchase 93,000 shares of Common Stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years, so long as the reporting person remains in the service of the Issuer on each such vesting date.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ John M. Gay</signatureName>
        <signatureDate>2026-04-20</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
